

7 July 2026

Treatment of Melanoma

1. How many patients have been treated in the past 3 months with the following agents for melanoma (any stage):

• Cobimetinib	0
• Dabrafenib	<5
• Dabrafenib + Trametinib	21
• Dacarbazine	0
• Denosumab	0
• Encorafenib + Binimetinib	29
• Ipilimumab monotherapy	0
• Ipilimumab + Nivolumab	16
• Nivolumab monotherapy	10
• Nivolumab + Relatlimab	5
• Pembrolizumab	39
• Pembrolizumab injection (Subcutaneous)	0
• Trametinib	0
• Vemurafenib	0
• Vemurafenib + Cobimetinib	0
• Other active systemic anti-cancer therapy - Tebentafusp	<5
• Palliative care only	Not available

2. In the last 3 months, how many patients have been initiated* on the following agents for treatment for melanoma? *Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

• Ipilimumab (monotherapy)	0
• Nivolumab (monotherapy)	0
• Nivolumab AND Ipilimumab (combination)	12
• Nivolumab AND Relatlimab	<5
• Pembrolizumab	10
• Any Targeted Therapy (Dabrafenib /Dabrafenib AND Trametinib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib)	5
• Other active systemic anti-cancer therapy - Tebentafusp	<5

Use of <5 (less than five): We are unable to provide an exact figure - exempt from release under Section 40(2) of the Freedom of Information Act - Personal Information relating to a third party, as the small numbers involved could make patients personally identifiable. Disclosure would constitute a breach of the principles of the General Data Protection Regulation 2018.

7 July 2026

3. Does your Trust participate in any clinical trials for Melanoma? If so, please provide the name of each trial, and the number of patients taking part.

Melanoma Open Trials – NI Cancer Trials Network - Belfast Trust 18/06/26		
Project Short title	Project Full title	Recruited (org)
PerceVe	Power of liquid biopsy tracking in immunotherapy treated stage III and IV melanoma (PerceVe)	7